Zacks Lowers Osiris Therapeutics to Neutral (OSIR)
Osiris Therapeutics (NASDAQ:OSIR) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a report issued on Friday. They currently have a $15.00 target price on the stock. Zacks‘s price target would suggest a potential upside of 6.01% from the stock’s previous close.
Zacks’ analyst wrote, “Osiris reported a loss of $0.04 per share in the second quarter of 2014, a penny narrower than the year-ago loss of $0.05. The Zacks Consensus Estimate was earnings of $0.30 per share. Revenues came in at $13.3 million, above the Zacks Consensus Estimate of $11 million and up 151.2% y-o-y. Osiris’ Biosurgery segment has been gaining traction over the past few quarters. The company’s increased sales effort should start paying off from the second half of the year. We are also positive on the company’s sale of its ceMSC business which has not only brought in cash for Osiris in the form of an upfront payment but will also bring in royalties. While encouraged by the company’s progress with its Biosurgery business, we remain concerned about the dependence on a single segment for growth. We are moving back to a Neutral recommendation.”
Osiris Therapeutics (NASDAQ:OSIR) traded up 0.92% on Friday, hitting $14.28. The stock had a trading volume of 85,436 shares. Osiris Therapeutics has a 1-year low of $11.80 and a 1-year high of $19.75. The stock’s 50-day moving average is $14.58 and its 200-day moving average is $14.83. The company has a market cap of $489.9 million and a price-to-earnings ratio of 10.70.
Osiris Therapeutics (NASDAQ:OSIR) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.04) earnings per share for the quarter, missing the analysts’ consensus estimate of $0.16 by $0.20. The company had revenue of $13.30 million for the quarter, compared to the consensus estimate of $11.00 million. Analysts expect that Osiris Therapeutics will post $-0.01 EPS for the current fiscal year.
Osiris Therapeutics, Inc (NASDAQ:OSIR), is a stem cell therapeutic company.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.